In The News

Dominique Hussey in Bloomberg on Canada's Pharmaceutical IP Rules

July 26, 2017
Social Media
Download
Download
Read Mode
Subscribe
Summarize

Dominique Hussey comments in Bloomberg BNA on draft changes to Canada's patent litigation process for prescription drugs. She points out that the changes create new opportunities and challenges, introduce complexity into the litigation and will raise new procedural and substantive issues that have no precedent. The amendments could take effect as early as September 21, 2017, when the Comprehensive Economic Trade Agreement (CETA) that inspired the changes will be provisionally applied.

Social Media
Download
Download
Subscribe
Republishing Requests

For permission to republish this or any other publication, contact Peter Zvanitajs at ZvanitajsP@bennettjones.com.

For informational purposes only

This publication provides an overview of legal trends and updates for informational purposes only. For personalized legal advice, please contact the authors.

From the Same Authors

See All
Placeholder
Article

WTR: Trademark Litigation Review 2024

December 12, 2023
Dominique T. HusseyMelissa M. Dimilta
Dominique T. Hussey & Melissa M. Dimilta
Placeholder
Article

Winning Strategies for Litigating Before Canadian Courts

November 24, 2023
Dominique T. HusseyMelissa M. Dimilta
Dominique T. Hussey & Melissa M. Dimilta
IWD 2023 Workplaces Where Women Thrive
Update

IWD 2023: Workplaces Where Women Thrive

March 8, 2023
Melanie L. AitkenDominique T. HusseyPatrick T. Maguire KC
& 2 more

Latest Insights

See All Insights
Policy Dual Use and DefTech Drive a New Era for Private Capital in Defence
Blog

Policy, Dual-Use and DefTech Drive a New Era for Private Capital in Defence

November 15, 2025
Andrew BozzatoBishoy Attia
Andrew Bozzato & Bishoy Attia
Placeholder
Article

Bennett Jones on Tax Disputes: November 2025

November 6, 2025
Edwin G. Kroft KCAntoine MesservierAnna Lekach
Edwin G. Kroft KC, Antoine Messervier & Anna Lekach